PRVAHealthcare · Health Information ServicesThe 19 Wall Street analysts covering Privia Health Group, Inc. hold a median 12-month price target of $31 — +54.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 17 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Privia Health Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (83): The share price has been relatively steady.
Issuance (42): The company has been issuing shares or taking on financing, diluting existing holders.
Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PRVA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +54.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 May 2026 | Barclays | Maintains | Equal-Weight | $25 → $24 |
| 8 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 25 Mar 2026 | Barclays | Maintains | Equal-Weight | — |
| 3 Mar 2026 | Citigroup | Maintains | Buy | — |
| 2 Mar 2026 | Truist Securities | Maintains | Buy | — |
| 27 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 9 Jan 2026 | RBC Capital | Reinstates | Outperform | $31 |
| 4 Dec 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 13 Nov 2025 | BMO Capital | Initiates | Outperform | — |
| 13 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 12 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 10 Nov 2025 | Barclays | Maintains | Equal-Weight | — |
| 10 Nov 2025 | Truist Securities | Reiterates | Buy | — |
| 7 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 7 Nov 2025 | Evercore ISI Group | Maintains | Outperform | — |
| 9 Oct 2025 | Barclays | Maintains | Equal-Weight | — |
| 24 Sept 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 4 Sept 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 29 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRVA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 17 Sept 2026, Privia Health Group, Inc. returned −9.5% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 7% of US stocks
Cheaper than 67% of US stocks
Cheaper than 30% of US stocks
Cheaper than 6% of US stocks
Higher than 71% of US stocks
Higher than 91% of US stocks
Higher than 9% of US stocks
Higher than 48% of US stocks
Higher than 50% of US stocks
Higher than 52% of US stocks
Higher than 59% of US stocks
Higher than 21% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Privia Health Group, Inc. has a market value of $2.6B and an enterprise value of $2.3B.
Revenue in the twelve months to 30 June 2026: $2.4B. The latest quarter grew 21.4% year on year.
Net income over the same four quarters: $33.8M, a 1.4% net margin.
Diluted earnings per share, trailing twelve months: $0.21.
Free cash flow in the twelve months to 30 June 2026: $131.1M.
Trailing P/E: 97.0×; forward P/E: 19.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.98%, paying out 0% of earnings.
Privia Health Group, Inc. employs 1,226 people — $1.9M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Privia Health Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Privia Health Group, Inc. announced the appointment of Opella Ernest, M.D. to its Board of Directors. The announcement was made by the company on August 18, 2026.
Why it matters — A PRVA watcher would care because the addition of a new director brings new governance experience and perspective to the company's board.
Privia Health Group reported second-quarter results with double-digit growth in implemented providers, attributed lives, and practice collections, while adjusted EBITDA rose 29% year over year. Management raised its 2026 outlook for several financial measures following what CEO Parth Mehrotra described as strong first-half execution.
Why it matters — A PRVA watcher would care because the company reported broad operational growth and raised its 2026 guidance, indicating improving financial momentum.
Privia Health Group, Inc. held its Q2 2026 earnings call, with the transcript of that event published by Seeking Alpha.
Why it matters — The earnings call transcript provides investors and analysts with management's discussion of the company's quarterly financial results and operational performance.
Zacks Investment Research reported on Privia Health's second-quarter (ended June 2026) earnings, examining its revenue and EPS and comparing key metrics against Wall Street estimates and year-ago figures to gauge how the business performed.
Why it matters — A PRVA watcher would care because the report shows how the company's headline revenue and EPS, along with other key metrics, measured up against analyst expectations for the quarter.
Privia Health reported Q2 earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.02 per share in the same quarter a year ago.
Why it matters — The earnings miss versus analyst expectations signals a shortfall against consensus for the quarter, which PRVA watchers would track closely.
The 19 Wall Street analysts covering Privia Health Group, Inc. have a median 12-month price target of $31, with estimates ranging from $24 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 19 analysts covering Privia Health Group, Inc., 18 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Privia Health Group, Inc. 66 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 17 Sept 2026, Privia Health Group, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (83 of 100).
No one can know that. What the data says: the median 12-month target from 19 analysts implies +54.3% from the last close, and Ticker Nerd's factor model ranks Privia Health Group, Inc. 66 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Privia Health Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $40 over the next 12 months.
Privia Health Group, Inc. returned -9.5% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Privia Health Group, Inc. is a technology-driven physician enablement company focused on helping medical groups, health plans, and health systems improve the delivery of care.
The most recent item we track (GlobeNewsWire, 18 Aug 2026): "Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors". Privia Health Group, Inc. announced the appointment of Opella Ernest, M.D. to its Board of Directors. The announcement was made by the company on August 18, 2026.
Privia Health Group, Inc. is a technology-driven physician enablement company focused on helping medical groups, health plans, and health systems improve the delivery of care. Privia Health’s current platform combines cloud-based technology, population health tools, management services, and clinically integrated network capabilities to support providers in coordinating patient care, reducing administrative burden, and operating more efficiently. The company works across in-person and virtual care settings, with services that help independent physicians align clinical workflows, manage value-based care arrangements, and strengthen collaboration across practices. Privia Health also operates risk-bearing and accountable care models that are designed to support coordinated, high-value care for patients and providers. Based in Arlington, Virginia, Privia Health Group serves a broad national provider network and plays a significant role in the healthcare services and health information services markets.
CEO Mr. Parth Mehrotra · 1,226 employees · United States · https://www.priviahealth.com
